Eyecare

Vision Health Company Raises $6.4M to Develop Dry-Eye Product

It’s conducting a study in Sjögren’s syndrome dry eye patients.

Published

5 years ago

April 10, 2019

TearSolutions Inc., a Charlottesville, VA-based biopharmaceutical company, announced the completion of a $6.4 million financing round.

The company will use the funds to complete a pivotal FDA Phase II clinical trial for LacripepTM, its lead product candidate.

The clinical trial is being conducted with 201 primary Sjögren’s syndrome dry eye patients at 27 investigational sites across the U.S. A new site is opening soon at the University of Virginia.

LacripepTM is a naturally occurring peptide found in normal tears that has been shown to be deficient in all forms of dry eye tears.

Primary Sjögren’s syndrome patient’s tears are particularly deficient in LacripepTM, according to a press release from the company. Administration of LacripepTM in a Sjögren’s animal model has shown “a dramatic restoration of normal tearing and corneal health.”

“The dry eye market in the US is just over $2 billion, and neither of the two FDA approved products address the root cause,” said Dr. Tom Gadek, president and CEO of the company.

“As a natural replacement therapy, LacripepTM could meet a huge unmet need.”

INVISION Staff

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

click to Comment(Comment)

Up Next

Shopko to Auction Optical Business, Possibly Keeping 80 Locations Open

Don't Miss

Alcon Debuts As Independent Company

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width³ according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion⁴ and seamless transitions from near to far.

For more information, visit here.